Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
From BioSpace · · 17 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.